Mineralys Therapeutics, Inc. (MLYS)Healthcare | Biotechnology | Radnor, United States | NasdaqGS
30.58 USD
+0.02
(0.065%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 30.58 Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:01 p.m. EDT
Mineralys Therapeutics (MLYS) presents a high-risk, high-reward scenario with significant volatility. The recent price movements show a lack of consistent direction, and the fundamental data indicates negative earnings and a high overall risk profile. The options activity suggests a mix of bullish and bearish sentiment, with potential for both upward and downward price movements. The lack of dividend history and the negative financial metrics make it a risky investment for both short-term and long-term investors. While there may be opportunities for speculation, the overall outlook is not favorable for most investors. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.167567 |
| AutoETS | 0.167567 |
| MSTL | 0.168960 |
| AutoTheta | 0.205818 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 49% |
| H-stat | 4.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.369 |
| Excess Kurtosis | -0.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 2,521,380,608 |
| Forward P/E | -16.71 |
| Beta | 0.69 |
| Website | https://mineralystx.com |
As of April 11, 2026, 4:01 p.m. EDT: Options speculators are showing mixed signals. The calls show a concentration of open interest and volume on the upside, particularly on strikes like 30.0 and 45.0, suggesting some bullish sentiment. However, the puts also have significant open interest on the downside, especially around strikes like 17.5 and 22.5, indicating potential bearish positioning. The high implied volatility (IV) across multiple expirations suggests uncertainty or heightened expectations for future price movements. The overall activity implies a volatile environment with potential for both upward and downward moves.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3096676 |
| Address1 | 150 N. Radnor Chester Road |
| Address2 | Suite F200 |
| All Time High | 47.65 |
| All Time Low | 5.85 |
| Ask | 31.29 |
| Ask Size | 13 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 1,337,410 |
| Average Daily Volume3 Month | 1,246,646 |
| Average Volume | 1,246,646 |
| Average Volume10Days | 1,337,410 |
| Beta | 0.69 |
| Bid | 29.95 |
| Bid Size | 13 |
| Board Risk | 9 |
| Book Value | 7.931 |
| City | Radnor |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 30.58 |
| Current Ratio | 43.763 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 31.33 |
| Day Low | 30.045 |
| Display Name | Mineralys Therapeutics |
| Earnings Call Timestamp End | 1,773,347,400 |
| Earnings Call Timestamp Start | 1,773,347,400 |
| Earnings Timestamp | 1,773,345,600 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -170,544,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -10.925 |
| Enterprise Value | 1,863,140,992 |
| Eps Current Year | -2.09571 |
| Eps Forward | -1.83 |
| Eps Trailing Twelve Months | -2.29 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 27.3908 |
| Fifty Day Average Change | 3.1891994 |
| Fifty Day Average Change Percent | 0.11643323 |
| Fifty Two Week Change Percent | 130.96677 |
| Fifty Two Week High | 47.65 |
| Fifty Two Week High Change | -17.070002 |
| Fifty Two Week High Change Percent | -0.35823718 |
| Fifty Two Week Low | 12.59 |
| Fifty Two Week Low Change | 17.99 |
| Fifty Two Week Low Change Percent | 1.4289118 |
| Fifty Two Week Range | 12.59 - 47.65 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,676,039,400,000 |
| Float Shares | 60,258,738 |
| Forward Eps | -1.83 |
| Forward P E | -16.710382 |
| Free Cashflow | -84,379,504 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0072399997 |
| Held Percent Institutions | 1.13708 |
| Implied Shares Outstanding | 82,451,950 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-02-10 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. |
| Long Name | Mineralys Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,521,380,608 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_710468587 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -154,651,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,518,082,553 |
| Number Of Analyst Opinions | 8 |
| Open | 31.33 |
| Operating Cashflow | -142,416,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 888 378 6240 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 30.58 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 30.56 |
| Price Eps Current Year | -14.591713 |
| Price Hint | 2 |
| Price To Book | 3.8557558 |
| Profit Margins | 0.0 |
| Quick Ratio | 43.448 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0200005 |
| Regular Market Change Percent | 0.0654465 |
| Regular Market Day High | 31.33 |
| Regular Market Day Low | 30.045 |
| Regular Market Day Range | 30.045 - 31.33 |
| Regular Market Open | 31.33 |
| Regular Market Previous Close | 30.56 |
| Regular Market Price | 30.58 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,013,502 |
| Return On Assets | -0.24576999 |
| Return On Equity | -0.36912 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 82,451,950 |
| Shares Percent Shares Out | 0.1015 |
| Shares Short | 8,370,090 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 9,607,513 |
| Short Name | Mineralys Therapeutics, Inc. |
| Short Percent Of Float | 0.1233 |
| Short Ratio | 5.86 |
| Source Interval | 15 |
| State | PA |
| Symbol | MLYS |
| Target High Price | 56.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 49.375 |
| Target Median Price | 51.5 |
| Total Cash | 656,635,008 |
| Total Cash Per Share | 7.969 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.29 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 30.31805 |
| Two Hundred Day Average Change | 0.26194954 |
| Two Hundred Day Average Change Percent | 0.008640052 |
| Type Disp | Equity |
| Volume | 1,013,502 |
| Website | https://mineralystx.com |
| Zip | 19,087 |